DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM) has been assigned an average recommendation of “Moderate Buy” from the eighteen analysts that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $104.59.

Several equities analysts have commented on the company. Wells Fargo & Company upped their price objective on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Leerink Partners cut their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Stifel Nicolaus lifted their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. JPMorgan Chase & Co. boosted their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target on shares of DexCom in a research note on Monday, August 26th.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $77.83 on Tuesday. The company has a market capitalization of $30.40 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 2.23 and a beta of 1.17. The firm’s 50-day moving average is $70.76 and its 200 day moving average is $88.93. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is owned by corporate insiders.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently made changes to their positions in DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in DexCom in the second quarter valued at $25,000. Sachetta LLC lifted its holdings in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares during the period. Crewe Advisors LLC acquired a new position in shares of DexCom in the 1st quarter valued at about $29,000. Riverview Trust Co boosted its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares during the last quarter. Finally, DT Investment Partners LLC grew its holdings in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.